首页 | 本学科首页   官方微博 | 高级检索  
检索        

慢性肾衰竭透析前患者促红细胞生成素的应用
引用本文:杨沐,刁秀竹,任伟,柴树人.慢性肾衰竭透析前患者促红细胞生成素的应用[J].中国血液净化,2003,2(2):79-81.
作者姓名:杨沐  刁秀竹  任伟  柴树人
作者单位:230001,合肥,安徽省立医院肾内科
摘    要:目的 探讨rHuEPO治疗慢性肾衰竭透析前患者贫血的安全和可靠性。方法 采用随机前后自身对照的研究方法,给予46例慢性肾衰竭透析前贫血患者rHuEPO皮下注射,3000u/次,2次/周,观察疗程12周。结果 46例治疗患者显效26例,显效率56.5%,有效18例占39.1%,无效2例占4.3%,总有效率95.6%。治疗前后肝、肾功能,血电解质改变无明显差异(P>0.05)。结论 rHuEPO治疗慢性肾衰竭透析前贫血患者疗效可靠、安全,不会使肾功能恶化,主要不良反应为高血压。

关 键 词:慢性肾衰竭  促红细胞生成素  贫血  血液透析  疗效
修稿时间:2002年8月19日

Effects of rHuEPO in chronic renal failure predialysis patient
YANG Mu,DIAO Xiuzhu,REN Wei,et al..Effects of rHuEPO in chronic renal failure predialysis patient[J].Chinese Journal of Blood Purification,2003,2(2):79-81.
Authors:YANG Mu  DIAO Xiuzhu  REN Wei  
Institution:YANG Mu,DIAO Xiuzhu,REN Wei,et al. Department of Nephrology,The People' s Hospital of Anhui Province,Hefei 230001,China
Abstract:Objective To determine the effectiveness and safety of rHuEPO madein chronic renal failure predialysis patient.Method using random, oneself contrasted method. 46 cases chronic renal failure predialysis patients received rHuEPO subcutaneouly, two times per week. The duration of rHuEPO therapy was 12weeks. Results Remarkable improvement rate of patient was 56.5% (26/46) . Significant improvement rate of patient was 39.1% (18/46) . No effectiveness rate of patient was 4.3% (2/46) . Conclusions In our study, the treatment of chronic renal anemia predialysis-patinent with rHuEPO was effectiveness and safety. rHuEPO related side effects was hypertension in 7 (15.2% ) patient.
Keywords:Erythropoietin  Anemia  Early treatment  Chronic failure
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号